NEOS Investment Management LLC Has $565,000 Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

NEOS Investment Management LLC boosted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 28.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 35,663 shares of the company’s stock after purchasing an additional 7,885 shares during the period. NEOS Investment Management LLC owned 0.09% of Keros Therapeutics worth $565,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Victory Capital Management Inc. bought a new position in shares of Keros Therapeutics in the 3rd quarter valued at about $216,000. Intech Investment Management LLC bought a new position in Keros Therapeutics during the third quarter worth about $603,000. Charles Schwab Investment Management Inc. increased its position in Keros Therapeutics by 14.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after buying an additional 32,492 shares during the last quarter. FMR LLC raised its stake in Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Keros Therapeutics by 59.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock valued at $312,000 after buying an additional 1,994 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Trading Down 1.8 %

NASDAQ KROS opened at $10.79 on Monday. The company has a market cap of $437.66 million, a price-to-earnings ratio of -2.07 and a beta of 1.39. The company has a 50 day moving average of $11.15 and a 200-day moving average of $34.30. Keros Therapeutics, Inc. has a 1-year low of $9.78 and a 1-year high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. On average, equities research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on KROS. Wells Fargo & Company dropped their price target on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Truist Financial cut their target price on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. HC Wainwright reduced their target price on shares of Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, February 27th. TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Wedbush cut Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $47.00 to $15.00 in a report on Friday, January 17th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.